http://orcid.org/0000-0002-8619-412X
Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Neel R. Nabar, Christopher N. Heijjer, Chong-Shan Shi, Il-Young Hwang, Sundar Ganesan, Mikael C. I. Karlsson & John H. Kehrl. (2022) LRRK2 is required for CD38-mediated NAADP-Ca2+ signaling and the downstream activation of TFEB (transcription factor EB) in immune cells. Autophagy 18:1, pages 204-222.
Read now
Read now
Yaru Feng, Xiuying Liu, Xiaorui Li, Yating Zhou, Zhiru Song, Jing Zhang, Bingjie Shi & Jianxun Wang. (2021) Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. OncoImmunology 10:1.
Read now
Read now
Luca Bertamini, Francesca Bonello, Mario Boccadoro & Sara Bringhen. (2020) New drugs in early development for treating multiple myeloma: all that glitters is not gold. Expert Opinion on Investigational Drugs 29:9, pages 989-1004.
Read now
Read now
Pellegrino Musto & Francesco La Rocca. (2020) Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence. Expert Review of Hematology 13:5, pages 501-517.
Read now
Read now
Pellegrino Musto & Francesco La Rocca. (2020) Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses. Expert Review of Hematology 13:4, pages 331-349.
Read now
Read now
Articles from other publishers (19)
Wioletta Olejarz & Grzegorz Basak. (2023) Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies. Cancers 15:24, pages 5765.
Crossref
Crossref
Manlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, Alessandro Allegra, Uroš Markovic, Cirino Botta, Fabrizio Accardi, Iolanda Donatella Vincelli, Salvatore Leotta, Federica Elia, Benedetta Esposito, Bruno Garibaldi, Gabriele Sapuppo, Alessandra Orofino, Alessandra Romano, Giuseppe A. Palumbo, Francesco Di Raimondo & Concetta Conticello. (2023) Multiple Myeloma in 2023 Ways: From Trials to Real Life. Current Oncology 30:11, pages 9710-9733.
Crossref
Crossref
Jinrong Yang, Weilin Zhou, Dan Li, Ting Niu & Wei Wang. (2023) BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Cancer Letters 553, pages 215949.
Crossref
Crossref
Zehua Wang, Chen Chen, Lei Wang, Yongxu Jia & Yanru Qin. (2022) Chimeric antigen receptor T-cell therapy for multiple myeloma. Frontiers in Immunology 13.
Crossref
Crossref
Irina V. Gribkova. (2022) CAR NK-сells for the treatment of hematological malignancies: A review. Journal of Modern Oncology 24:3, pages 331-335.
Crossref
Crossref
Yuhan Tu, Zhiang Yao, Wenjing Yang, Shanhui Tao, Bin Li, Yun Wang, Zhijian Su & Shijun Li. (2022) Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine. Frontiers in Nanotechnology 4.
Crossref
Crossref
Peipei Yang, Ying Qu, Mengyao Wang, Bingyang Chu, Wen Chen, Yuhuan Zheng, Ting Niu & Zhiyong Qian. (2022) Pathogenesis and treatment of multiple myeloma. MedComm 3:2.
Crossref
Crossref
Taewoong Choi & Yubin Kang. (2022) Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. Pharmacology & Therapeutics 232, pages 108007.
Crossref
Crossref
Ruiting Guo, Wenyi Lu, Yi Zhang, Xinping Cao, Xin Jin & Mingfeng Zhao. (2022) Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting. Frontiers in Immunology 13.
Crossref
Crossref
Wu Ye, Xia Wu, Xiaoyan Liu, Xue Zheng, Jili Deng & Yuping Gong. (2021) Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials. BMC Cancer 21:1.
Crossref
Crossref
Natalie Baum, Marie Eggers, Julia Koenigsdorf, Stephan Menzel, Julia Hambach, Tobias Staehler, Ralf Fliegert, Frederike Kulow, Gerhard Adam, Friedrich Haag, Peter Bannas & Friedrich Koch-Nolte. (2021) Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells. Frontiers in Immunology 12.
Crossref
Crossref
Hyun Tae Lee, Yujin Kim, Ui Beom Park, Tae Jun Jeong, Sang Hyung Lee & Yong-Seok Heo. (2021) Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma. Biochemical and Biophysical Research Communications 536, pages 26-31.
Crossref
Crossref
Mattia D’Agostino, Salvatore Innorcia, Mario Boccadoro & Sara Bringhen. (2020) Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. International Journal of Molecular Sciences 21:21, pages 8192.
Crossref
Crossref
Deming Feng & Jian Sun. (2020) Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Scandinavian Journal of Immunology 92:2.
Crossref
Crossref
Benjamin Motais, Sandra Charvátová, Matouš Hrdinka, Michal Šimíček, Tomáš Jelínek, Tereza Ševčíková, Zdeněk Kořístek, Roman Hájek & Juli R. Bagó. (2020) A Bird’s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. Cancers 12:5, pages 1333.
Crossref
Crossref
Mattia D'Agostino, Roberto Mina & Francesca Gay. (2020) Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?. The Lancet Haematology 7:5, pages e355-e357.
Crossref
Crossref
Mattia D’Agostino & Noopur Raje. (2019) Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. Leukemia 34:1, pages 21-34.
Crossref
Crossref
Francesca Bonello, Roberto Mina, Mario Boccadoro & Francesca Gay. (2019) Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers 12:1, pages 15.
Crossref
Crossref
Zhitao Gao, Chuan Tong, Yao Wang, Deyun Chen, Zhiqiang Wu & Weidong Han. (2019) Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. Journal of Genetics and Genomics 46:8, pages 367-377.
Crossref
Crossref